Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Prostatic Neoplasms 47Lung Neoplasms 43Neoplasm Metastasis 34Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 26Multiple Myeloma 24Glioma 22Pancreatic Neoplasms 21Carcinoma, Renal Cell 21Lymphoma, Large B-Cell, Diffuse 20Ovarian Neoplasms 19Melanoma 19Glioblastoma 19Squamous Cell Carcinoma of Head and Neck 18Lymphoma 18Urinary Bladder Neoplasms 17Colorectal Neoplasms 17Oropharyngeal Neoplasms 15Mouth Neoplasms 15Triple Negative Breast Neoplasms 14Brain Neoplasms 14Fallopian Tube Neoplasms 13Carcinoma 13Laryngeal Neoplasms 12Carcinoma, Hepatocellular 12Astrocytoma 12Leukemia, Myeloid, Acute 11Sarcoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neuroblastoma 10

Interventions

Cisplatin 11pembrolizumab 10Carboplatin 7Radiotherapy 6Cetuximab 6Docetaxel 5Surveys and Questionnaires 3Radiotherapy, Intensity-Modulated 3Paclitaxel 3Cyclophosphamide 3fludarabine 2cemiplimab 2atezolizumab 2aldesleukin 2Surgical Procedures, Operative 2Standard of Care 2Radiation 2Nivolumab 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Drug Therapy 2vistusertib 1toripalimab 1sitravatinib 1palbociclib 1osimertinib 1olaparib 1niraparib 1lenvatinib 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × Magnetic Resonance Spectroscopy × 90 days × Clear all
NCT03952585 2026-06-01

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
384 enrolled 22 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Oropharyngeal Neoplasms

NCT07217028 2026-05-11

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

Vanderbilt-Ingram Cancer Center

Phase 1 Recruiting
25 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡